Diabetes Obes Metab 2022 Jun 16. Epub 2022 Jun 16.
Department of Endocrinology and Metabolism, The People's Hospital of China Medical University, The People's Hospital of Liaoning Province, Shenyang, Liaoning Province, P.R.China.
Background: This study aimed to compare the efficacy of sodium-glucose cotransporter 2 (SGLT-2) inhibitors, non-steroidal mineralocorticoid receptor antagonist (MRA), selective aldosterone antagonist, and non-selective aldosterone antagonist on top of renin-angiotensin system (RAS) blockade in reducing kidney-specific composite events, cardiovascular outcomes, and other events of special interest in participants with type 2 diabetes (T2D) and chronic kidney disease (CKD).
Methods: PubMed, EMBASE, and CENTRAL were searched for studies published up to January 20, 2022. Randomized clinical trials enrolling participants with T2D and CKD were included, for which SGLT-2 inhibitors, non-steroidal MRA, selective aldosterone antagonist, and non-selsective aldosterone antagonists were compared with either each other, or placebo or no treatment. Read More